Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Erythromycin

FDA-approved product (ointment, ophthalmic), marketed as A/T/S, Akne-Mycin, C-Solve-2 and 34 more.

Registered studies
50+
Lab records
32
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Erythromycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Bacterial disease
  • Eye infection
  • Infection
  • Whooping cough

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives for treatment of acne; Macrolides; Antibiotics
FDA pharmacologic class
Macrolide; Macrolide Antimicrobial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF02; WHO ATC D10AF52; WHO ATC J01FA01; WHO ATC S01AA17

Repurposing investigation

Erythromycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis71.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 17 of 25 lab records
  • E. coli: measured active in 0 of 1 lab record
  • K. pneumoniae: measured active in 6 of 6 lab records
Open Erythromycin in ChEMBL Registered studies below
Show the 32 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Erythromycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Azithromycin in the Prevention of Lung Injury in Premature Newborn

    NCT03485703 · start 2012-08-28

    Registered record
    Registry ID
    NCT03485703
    Conditions
    Bronchopulmonary Dysplasia
    Interventions
    Azithromycin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-08-28
    Completion
    2016-04-13
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBronchopulmonary Dysplasia
    InterventionAzithromycin; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Personalized Treatment for Refractory H Pylori Infection

    NCT02547025 · start 2012-08-01

    Registered record
    Registry ID
    NCT02547025
    Conditions
    Helicobacter Pylori Infection
    Interventions
    rabeprazole+3 antibiotics; rabeprazole+bismuth+2 antibiotics; rabeprazole+amox+tetr+levo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2021-10-31
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionrabeprazole+3 antibiotics; rabeprazole+bismuth+2 antibiotics; rabeprazole+amox+tetr+levo
    PhaseNot applicable
    Registry statusCompleted

  • Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopy in Patients With Upper Gastrointestinal Bleeding

    NCT01716572 · start 2012-02

    Registered record
    Registry ID
    NCT01716572
    Conditions
    Gastrointestinal Hemorrhage; Hematemesis
    Interventions
    Erythromycin; gastric lavage
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2012-02
    Completion
    2015-12
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Hemorrhage; Hematemesis
    InterventionErythromycin; gastric lavage
    PhasePhase 3
    Registry statusUnknown

  • Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori

    NCT01505127 · start 2012-01

    Registered record
    Registry ID
    NCT01505127
    Conditions
    H. Pylori Infection
    Interventions
    TAK-438; Lansoprazole; Amoxicillin; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-06
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionH. Pylori Infection
    InterventionTAK-438; Lansoprazole; Amoxicillin; Clarithromycin
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

    NCT01454076 · start 2011-11-10

    Registered record
    Registry ID
    NCT01454076
    Conditions
    Nonhematologic Malignancies; Lymphoma
    Interventions
    Ixazomib 2.5 mg; Ixazomib 4 mg Capsule A; Ixazomib 4 mg Capsule B; Ketoconazole; Rifampin; Clarithromycin; Ixazomib 4 mg Capsule B
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11-10
    Completion
    2016-06-16
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNonhematologic Malignancies; Lymphoma
    InterventionIxazomib 2.5 mg; Ixazomib 4 mg Capsule A; Ixazomib 4 mg Capsule B; Ketoconazole +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

    NCT01309438 · start 2011-02

    Registered record
    Registry ID
    NCT01309438
    Conditions
    Healthy; Renal Insufficiency
    Interventions
    Rivaroxaban (normal renal function); Rivaroxaban (mild and moderate renal impairment); Erythromycin (normal renal function); Erythromycin (mild and moderate renal function)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    2012-03
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Renal Insufficiency
    InterventionRivaroxaban (normal renal function); Rivaroxaban (mild and moderate renal impairment); Erythromycin (normal renal function); Erythromycin (mild and moderate renal function)
    PhasePhase 1
    Registry statusCompleted

  • Tropisetron on Postoperative Pain

    NCT01304953 · start 2010-01

    Registered record
    Registry ID
    NCT01304953
    Conditions
    Pain, Postoperative
    Interventions
    Group P+P; Group P+T; Group S+P; Group S+T
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-12
    Enrolment
    296

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain, Postoperative
    InterventionGroup P+P; Group P+T; Group S+P; Group S+T
    PhasePhase 4
    Registry statusCompleted

  • Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea

    NCT01136850 · start 2009-11

    Registered record
    Registry ID
    NCT01136850
    Conditions
    Malaria in Pregnancy; Sexually Transmitted Infections; Anaemia
    Interventions
    chloroquine, sulphadoxine pyrimethamine, LLIN; azithromycin, sulphadoxine pyrimethamine, LLIN
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-11
    Completion
    2013-01
    Enrolment
    2,793

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria in Pregnancy; Sexually Transmitted Infections; Anaemia
    Interventionchloroquine, sulphadoxine pyrimethamine, LLIN; azithromycin, sulphadoxine pyrimethamine, LLIN
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media

    NCT00796224 · start 2008-12

    Registered record
    Registry ID
    NCT00796224
    Conditions
    Acute Otitis Media
    Interventions
    60 mg/kg azithromycin ER; 30 mg/kg azithromycin IR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-12
    Completion
    2009-02
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Otitis Media
    Intervention60 mg/kg azithromycin ER; 30 mg/kg azithromycin IR
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis

    NCT00629590 · start 2008-03

    Registered record
    Registry ID
    NCT00629590
    Conditions
    Blepharitis
    Interventions
    AzaSite®
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-03
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlepharitis
    InterventionAzaSite®
    PhasePhase 4
    Registry statusCompleted

  • Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

    NCT00621504 · start 2008-01

    Registered record
    Registry ID
    NCT00621504
    Conditions
    Bacterial Pneumonia
    Interventions
    Ceftaroline fosamil for Injection; IV Ceftriaxone; Placebo; Clarithromycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-06
    Enrolment
    606

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Pneumonia
    InterventionCeftaroline fosamil for Injection; IV Ceftriaxone; Placebo; Clarithromycin
    PhasePhase 3
    Registry statusCompleted

  • Microorganism in Overactive Bladder Patients

    NCT00883818 · start 2007-01

    Registered record
    Registry ID
    NCT00883818
    Conditions
    Overactive Bladder
    Interventions
    azithromycin, doxycycline
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2007-12
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder
    Interventionazithromycin, doxycycline
    PhasePhase 4
    Registry statusCompleted

  • Clarithromycin, Amoxicillin, and Metronidazole Based Regimens to Treat Helicobacter Pylori Infections in Colombia

    NCT00719420 · start 2006-04

    Registered record
    Registry ID
    NCT00719420
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole); Clarithromycin, Amoxicillin, Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-04
    Completion
    2007-02
    Enrolment
    151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionClarithromycin, Metronidazole, Amoxicillin (+Omeprazole); Clarithromycin, Amoxicillin, Omeprazole
    PhasePhase 3
    Registry statusCompleted

  • A Randomized, Open Label, Clinical Trial of the Pharmacokinetics of Azithromycin Following a Single Dose of Azithromycin Sustained Release (2 Gram) or Commercial Azithromycin Tablet (500 mg) to Cancer Patients That Require Lung Surgery

    NCT00644176 · start 2004-11

    Registered record
    Registry ID
    NCT00644176
    Conditions
    Pharmacokinetics
    Interventions
    azithromycin immediate release (Zithromax); placebo; azithromycin SR; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-11
    Completion
    2005-04
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics
    Interventionazithromycin immediate release (Zithromax); placebo; azithromycin SR; placebo
    PhasePhase 2
    Registry statusCompleted

  • Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum

    NCT00082563 · start 2004-08

    Registered record
    Registry ID
    NCT00082563
    Conditions
    Malaria, Falciparum
    Interventions
    Azithromycin/Chloroquine; Chloroquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2004-08
    Completion
    2004-11
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    InterventionAzithromycin/Chloroquine; Chloroquine
    PhasePhase 2
    Registry statusTerminated